Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.

Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, Foulkes WD, Witcher M.

Cancer Res. 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.

PMID:
30877105
2.

A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.

Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, Qiu D, Asslan M, Alaoui-Jamali MA.

Autophagy. 2019 Aug;15(8):1376-1390. doi: 10.1080/15548627.2019.1582951. Epub 2019 Mar 1.

PMID:
30773992
3.

MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.

Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr.

Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.

4.

Oncogenic activity of poly (ADP-ribose) glycohydrolase.

Marques M, Jangal M, Wang LC, Kazanets A, da Silva SD, Zhao T, Lovato A, Yu H, Jie S, Del Rincon S, Mackey J, Damaraju S, Alaoui-Jamali M, Witcher M.

Oncogene. 2019 Mar;38(12):2177-2191. doi: 10.1038/s41388-018-0568-6. Epub 2018 Nov 20.

5.

TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis.

da Silva SD, Xu B, Maschietto M, Marchi FA, Alkailani MI, Bijian K, Xiao D, Alaoui-Jamali MA.

Mol Cancer Ther. 2019 Jan;18(1):139-146. doi: 10.1158/1535-7163.MCT-17-1261. Epub 2018 Oct 29.

PMID:
30373932
6.

Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis.

Li L, Guturi KKN, Gautreau B, Patel PS, Saad A, Morii M, Mateo F, Palomero L, Barbour H, Gomez A, Ng D, Kotlyar M, Pastrello C, Jackson HW, Khokha R, Jurisica I, Affar EB, Raught B, Sanchez O, Alaoui-Jamali M, Pujana MA, Hakem A, Hakem R.

J Clin Invest. 2018 Oct 1;128(10):4525-4542. doi: 10.1172/JCI120401. Epub 2018 Aug 2.

7.

Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer.

Carnielli CM, Macedo CCS, De Rossi T, Granato DC, Rivera C, Domingues RR, Pauletti BA, Yokoo S, Heberle H, Busso-Lopes AF, Cervigne NK, Sawazaki-Calone I, Meirelles GV, Marchi FA, Telles GP, Minghim R, Ribeiro ACP, Brandão TB, de Castro G Jr, González-Arriagada WA, Gomes A, Penteado F, Santos-Silva AR, Lopes MA, Rodrigues PC, Sundquist E, Salo T, da Silva SD, Alaoui-Jamali MA, Graner E, Fox JW, Coletta RD, Paes Leme AF.

Nat Commun. 2018 Sep 5;9(1):3598. doi: 10.1038/s41467-018-05696-2.

8.

Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma.

Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, Miguel MC, Ferreira do Carmo A, Lambert DW, Graner E, Daniela da Silva S, Alaoui-Jamali MA, Paes Leme AF, Salo TA, Coletta RD.

Oncotarget. 2017 Aug 19;8(43):74736-74754. doi: 10.18632/oncotarget.20360. eCollection 2017 Sep 26.

9.

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV.

J Clin Invest. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.

10.

Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms.

Lubov J, Maschietto M, Ibrahim I, Mlynarek A, Hier M, Kowalski LP, Alaoui-Jamali MA, da Silva SD.

Oncotarget. 2017 Jul 13;8(33):55511-55524. doi: 10.18632/oncotarget.19224. eCollection 2017 Aug 15.

11.

Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer.

Bijian K, Kaldre D, Wang TT, Su J, Bouttier M, Boucher A, Alaoui-Jamali M, White JH, Gleason JL.

J Steroid Biochem Mol Biol. 2018 Mar;177:135-139. doi: 10.1016/j.jsbmb.2017.08.010. Epub 2017 Aug 25.

PMID:
28847749
12.

CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.

Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L, Witcher M.

Sci Adv. 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.

13.

Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells.

Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH Jr, Alaoui-Jamali MA.

Oncotarget. 2017 May 9;8(19):31199-31214. doi: 10.18632/oncotarget.16105.

14.

Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model.

Kahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S.

Appl Microbiol Biotechnol. 2017 Mar;101(5):1999-2019. doi: 10.1007/s00253-016-7885-x. Epub 2016 Nov 11.

PMID:
27837314
15.

Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2.

Saad A, Bijian K, Qiu D, da Silva SD, Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, Bismar T, Witcher M, Alaoui-Jamali MA.

Sci Rep. 2016 Nov 7;6:36699. doi: 10.1038/srep36699.

16.

Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression.

Nassour H, Wang Z, Saad A, Papaluca A, Brosseau N, Affar el B, Alaoui-Jamali MA, Ramotar D.

Sci Rep. 2016 Jul 8;6:29389. doi: 10.1038/srep29389.

17.

microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA.

Mol Biol Rep. 2016 Apr;43(4):229-40. doi: 10.1007/s11033-016-3948-4. Epub 2016 Feb 23.

PMID:
26907180
18.

Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis.

da Silva SD, Marchi FA, Xu B, Bijian K, Alobaid F, Mlynarek A, Rogatto SR, Hier M, Kowalski LP, Alaoui-Jamali MA.

Oncotarget. 2015 Sep 8;6(26):21950-63.

19.

Comment on "p38 MAPK inhibition alleviates experimental acute pancreatitis in mice".

Alaoui-Jamali M.

Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):330. No abstract available.

PMID:
26063037
20.

ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.

Alaoui-Jamali MA, Morand GB, da Silva SD.

Front Genet. 2015 Feb 4;6:17. doi: 10.3389/fgene.2015.00017. eCollection 2015. Review.

21.

Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I.

Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, Alaoui-Jamali MA, del Rincon SV, Ashworth T, Roy AL, Emerson BM, Witcher M.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E677-86. doi: 10.1073/pnas.1416674112. Epub 2015 Feb 2.

22.

Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma.

da Silva SD, Morand GB, Alobaid FA, Hier MP, Mlynarek AM, Alaoui-Jamali MA, Kowalski LP.

Clin Exp Metastasis. 2015 Jan;32(1):55-63. doi: 10.1007/s10585-014-9690-1. Epub 2014 Nov 30.

PMID:
25433796
23.

Insights into genetic and epigenetic determinants with impact on vitamin d signaling and cancer association studies: the case of thyroid cancer.

Morand GB, da Silva SD, Hier MP, Alaoui-Jamali MA.

Front Oncol. 2014 Nov 4;4:309. doi: 10.3389/fonc.2014.00309. eCollection 2014. Review.

24.

Dynamin 2 interacts with connexin 26 to regulate its degradation and function in gap junction formation.

Xiao D, Chen S, Shao Q, Chen J, Bijian K, Laird DW, Alaoui-Jamali MA.

Int J Biochem Cell Biol. 2014 Oct;55:288-97. doi: 10.1016/j.biocel.2014.09.021. Epub 2014 Sep 28.

PMID:
25263585
25.

Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease.

Gupta A, Lacoste B, Pistell PJ, Ingram DK, Hamel E, Alaoui-Jamali MA, Szarek WA, Vlahakis JZ, Jie S, Song W, Schipper HM.

J Neurochem. 2014 Dec;131(6):778-90. doi: 10.1111/jnc.12927. Epub 2014 Sep 6. Erratum in: J Neurochem. 2014 Dec;131(6):878. Pistel, Paul J [Corrected to Pistell, Paul J].

26.

The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.

Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, Alaoui-Jamali MA, Bismar TA.

Cancer Med. 2014 Feb;3(1):14-24. doi: 10.1002/cam4.168. Epub 2013 Dec 18.

27.

Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread.

Silva SD, Alaoui-Jamali MA, Hier M, Soares FA, Graner E, Kowalski LP.

Clin Exp Metastasis. 2014 Mar;31(3):307-16. doi: 10.1007/s10585-013-9629-y. Epub 2013 Dec 15.

PMID:
24338375
28.

Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine.

Bijian K, Lougheed C, Su J, Xu B, Yu H, Wu JH, Riccio K, Alaoui-Jamali MA.

Br J Cancer. 2013 Nov 26;109(11):2810-8. doi: 10.1038/bjc.2013.675. Epub 2013 Oct 29.

29.

TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target.

da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, Rogatto SR, Kowalski LP.

Cancer. 2014 Feb 1;120(3):352-62. doi: 10.1002/cncr.28404. Epub 2013 Oct 21.

30.

Total synthesis and biological activity of marine alkaloid Eudistomins Y1-Y7 and their analogues.

Jin H, Zhang P, Bijian K, Ren S, Wan S, Alaoui-Jamali MA, Jiang T.

Mar Drugs. 2013 Apr 29;11(5):1427-39. doi: 10.3390/md11051427.

31.

Recurrent oral cancer: current and emerging therapeutic approaches.

da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA.

Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012.

32.

Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.

Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU.

Oncogene. 2013 May 16;32(20):2527-33. doi: 10.1038/onc.2012.283. Epub 2012 Jul 16.

PMID:
22797066
33.

Molecular insights on basal-like breast cancer.

Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.

Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11. Review.

PMID:
22234518
34.

Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.

Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA.

Eur J Med Chem. 2012 Feb;48:143-52. doi: 10.1016/j.ejmech.2011.12.006. Epub 2011 Dec 9.

PMID:
22204902
35.

Total synthesis and bioactivity of the marine alkaloid pityriacitrin and some of its derivatives.

Zhang P, Sun X, Xu B, Bijian K, Wan S, Li G, Alaoui-Jamali M, Jiang T.

Eur J Med Chem. 2011 Dec;46(12):6089-97. doi: 10.1016/j.ejmech.2011.10.036. Epub 2011 Oct 25.

PMID:
22047643
36.

PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.

PMID:
21381033
37.

Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion.

Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA.

J Exp Med. 2010 Oct 25;207(11):2421-37. doi: 10.1084/jem.20100433. Epub 2010 Oct 11.

38.

A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.

Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM.

Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6.

39.

Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment.

Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA.

J Proteome Res. 2009 May;8(5):2173-85. doi: 10.1021/pr800979e.

PMID:
19284786
40.

Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.

Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA.

Clin Cancer Res. 2009 Feb 15;15(4):1376-83. doi: 10.1158/1078-0432.CCR-08-1789.

41.

Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.

Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA.

Br J Cancer. 2009 Feb 24;100(4):633-43. doi: 10.1038/sj.bjc.6604901. Epub 2009 Feb 3.

42.

Discovery of indoline-based, natural-product-like compounds as probes of focal adhesion kinase signaling pathways.

Poondra RR, Kumar NN, Bijian K, Prakesch M, Campagna-Slater V, Reayi A, Reddy PT, Choudhry A, Barnes ML, Leek DM, Daroszewska M, Lougheed C, Xu B, Schapira M, Alaoui-Jamali MA, Arya P.

J Comb Chem. 2009 Mar 9;11(2):303-9. doi: 10.1021/cc8001525.

PMID:
19146410
43.

Building skeletally diverse architectures on the Indoline Scaffold: the discovery of a chemical probe of focal adhesion kinase signaling networks.

Prakesch M, Bijian K, Campagna-Slater V, Quevillon S, Joseph R, Wei CQ, Sesmilo E, Reayi A, Poondra RR, Barnes ML, Leek DM, Xu B, Lougheed C, Schapira M, Alaoui-Jamali M, Arya P.

Bioorg Med Chem. 2008 Nov 1;16(21):9596-602. doi: 10.1016/j.bmc.2008.09.025. Epub 2008 Sep 12.

PMID:
18835181
44.
45.

Early stage cancer cell invasion: signaling, biomarkers and therapeutic targeting.

Behmoaram E, Bijian K, Bismar TA, Alaoui-Jamali MA.

Front Biosci. 2008 May 1;13:6314-25. Review.

PMID:
18508662
46.

A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma.

Mlynarek AM, Balys RL, Su J, Hier MP, Black MJ, Alaoui-Jamali MA.

Arch Otolaryngol Head Neck Surg. 2007 Sep;133(9):910-8.

PMID:
17875858
48.

Substituted 6-amino-4H-[1,2]dithiolo[4,3-b]pyrrol-5-ones: synthesis, structure-activity relationships, and cytotoxic activity on selected human cancer cell lines.

Li B, Lyle MP, Chen G, Li J, Hu K, Tang L, Alaoui-Jamali MA, Webster J.

Bioorg Med Chem. 2007 Jul 1;15(13):4601-8. Epub 2007 Apr 19.

PMID:
17467996
49.

Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth.

Darwish H, Cho JM, Loignon M, Alaoui-Jamali MA.

Oncogene. 2007 Jun 21;26(29):4319-28. Epub 2007 Jan 29.

PMID:
17260023
50.

Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.

Alaoui-Jamali MA.

Biomed Pharmacother. 2006 Nov;60(9):629-32. Epub 2006 Aug 28. Review.

PMID:
16949787

Supplemental Content

Loading ...
Support Center